EDGEMOND JAMES sold $14K of UTHR
EDGEMOND JAMES (CFO AND TREASURER) sold 25 shares of UNITED THERAPEUTICS Corp (UTHR) at $559.58 on 2026-05-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure may slightly influence short-term sentiment, but 10b5-1 pre-arrangement generally implies the trades were scheduled in advance and are not a real-time signal.
Market read
A routine 10b5-1 insider sale with no accompanying operational or clinical news for United Therapeutics.
What to watch
Insider sales can still matter if they cluster across multiple executives or if subsequent filings show acceleration; this article provides only one small sale.
Background
The article is an SEC Form 4 insider transaction disclosure for United Therapeutics, filed the day after the sale.
Ticker impact
United Therapeutics CFO and treasurer Edgemond James sold 25 shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Low probability of sustained price impact; any effect is likely limited to intraday/short-term sentiment.
The filing specifies an open-market sale and a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.
Market effects
Minimal; no drug, trial, or regulatory catalyst is mentioned—only an insider transaction.
None indicated.
None indicated.
Counterpoint
Because the sale is small and 10b5-1-based, it may be more consistent with liquidity/compensation than bearish expectations.
Key entities
- issuerUnited Therapeutics Corp
Issuer of the securities sold by the CFO/treasurer under a 10b5-1 plan.
- insiderEdgemond James
CFO and treasurer who executed the open-market sale of 25 shares.
